

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Bendamustine in combination with rituximab for the first-line treatment of mantle cell lymphoma

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

No

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

No issues relating to equality have been included in the scope.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No additional stakeholders were identified so no changes to the matrix were needed.

Approved by Associate Director: Janet Robertson

Date: 7th December 2013